Japan Generic Drugs Market Opportunity and Forecast AssessmentPosted by sunny on May 20th, 2019 Generic drugs are pharmaceutical drugs with similar chemical makeup of a branded drug. Generic drugs are subjected to government regulations of Japan; the Japanese Government has observed the growth of the generic drug market as imperative to Japans long-term economic health. The major factors that contribute to the growth of the Japan generic drugs market include increasing prevalence of chronic diseases, diabetes & cardiovascular diseases, rising costs of branded medicines, growth in geriatric population, increasing healthcare expenditure, and high demand for generic medicines. However, issues such as the consistency and stability of generic drugs in Japan and lower reimbursement fees are expected to restrain the market development. Development of reliable & stable new product launch, support from the government, and adoption of mergers & acquisition strategies to launch new products by key vendors contribute to significant demand for generic drugs in the near future. Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/4151 The Japan generic drugs market is segmented on the basis of product type, application, and distribution channel. On the basis of product type, the market is segmented into generic prescription medicines, super generics, and biosimilars. Based on application the market is divided into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. On the basis of distribution channel, the market is segmented into hospitals, pharmacies, private clinics, drug stores, retail pharmacies, and others. The key players that operate in this market include Teva Pharmaceutical Industries Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Sawai Pharmaceuticals Co., Ltd., NIPRO Medical Corporation, Meiji Seika Pharma Co., Ltd., Towa Pharmaceutical Co., Ltd., Hikari Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Mylan N.V., and GlaxoSmithKline Plc. Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4151
Key Benefits
Like it? Share it!More by this author |